Merck’s Covid-19 Drug Is a Boon for Wall Street and Main Street – Wsj

By revealing strong data for its experimental Covid-19 antiviral treatment , Merck MRK 8.37% & Co. and its partner Ridgeback Biotherapeutics have apparently struck a major blow against the pandemic. The news also has rejuvenated Merck’s stock price and could jump-start the moribund biotech sector. Merck and closely held Ridgeback Biotherapeutics said Friday their oral drug molnupiravir reduced the risk of hospitalization or death by about 50% in patients with mild to moderate Covid-19.

Read the source article at wsj.com
2021-10-01 14:49:00